Scientific Advisory Board

Dr. Norton is Senior Vice President, Office of the President, Memorial
Sloan Kettering Cancer Center; Professor of Medicine, Weill-Cornell
Medical College. He is a founder and Scientific Director of the Breast
Cancer Research Foundation. Dr. Norton is the founding incumbent of the
Norna S. Sarofim Chair of Clinical Oncology at MSKCC and a Professor of
Medicine in the Weill Cornell Medical College. He was a U.S. Presidential
appointee to the National Cancer Advisory Board (the board of directors of
the NCI) serving as Chair of the Budget Sub-Committee. A former Director of
the American Society of Clinical Oncology, he served as President of ASCO and
ubsequently Chair of the ASCO Foundation, now the Conquer Cancer Foundation.
He has been Vice-Chair of the Lymphoma Committee and a long-serving Chair of
the Breast Committee of the Cancer and Leukemia Group B (now the Alliance for
Clinical Trials in Oncology). He has served on or chaired numerous committees
of the National Cancer Institute, National Institutes of Health, and the
Institute of Medicine of the National Academy of Sciences. He is an editorial
board member or reviewer for numerous medical journals and on the advisory
boards of many advocacy and medical institutions including the Cold Spring
Harbor Laboratory Cancer Center and several Specialized Programs of Research
Excellence. Dr. Norton’s personal research has focused on the use of medicines
to treat cancer, particularly the application of mathematical methods to
optimizing dose and schedule. He has been involved in the development of
several effective agents including paclitaxel and trastuzumab. He co-invented
the Norton-Simon Model of cancer growth which has broadly influenced cancer
therapy, and more recently the self-seeding concept of cancer metastasis and
growth. He is the Principal Investigator of an NCI Program Project Grant in
Models of Human Breast Cancer and an author of more than 350 published articles
and many book chapters. He received his AB with Highest Distinction from
the University of Rochester and his MD from the College of Physicians and
Surgeons of Columbia University. He trained in medicine and medical research
at the Albert Einstein College of Medicine and the National Cancer Institute
(NCI).

Dr. Chawla holds medical licensures in both Texas and California, and he is board certified in Internal
Medicine and Medical Oncology He is a pioneering physician whose work in
sarcoma oncology has brought him several accolades and recognition as one
of the world’s leading authorities in medical treatment and clinical research
for bone and soft-tissue sarcomas and sarcoma therapy. Dr.
Chawla heads the Sarcoma Oncology Center in Santa Monica, CA. Dr.
Chawla serves on the clinical faculty of numerous prestigious cancer centers,
including UCLA, USC, John Wayne Cancer Institute at St. John’s Hospital; he has
been an adjunct associate professor at Stanford University and is an adjunct associate
professor at the University of Texas, M.D. Anderson Cancer Center; and he is a medical
oncologist at Cedars Sinai Comprehensive Cancer Center. Over his 30 years of medical and
clinical research experience, Dr. Chawla’s research has been a foundation for further
breakthroughs in cancer treatment. Dr. Chawla received his medical degree and completed his
residency training in Internal Medicine at the All India Institute of Medical Sciences in
New Delhi

Dr. Kurzrock joined University of California San Diego Moores Cancer
Center in November 2012 as Senior Deputy Center Director for Clinical
Science. She is also the Murray Professor of Medicine, Director of the
Clinical Trials Office and, on July 1, 2014, became the Chief of the
Division of Hematology-Oncology Division (in the UC San Diego School
of Medicine) . Dr. Kurzrock’s charge includes growing and innovating
the clinical trials program, and heading the newly established Center
for Personalized Cancer Therapy and the UCSD Moores Cancer Center
Clinical Trials Office. Dr. Kurzrock is best known for successfully
creating and chairing the largest Phase I clinical trials department in
the world while at the University of Texas M.D. Anderson Cancer Center.
Dr. Kurzrock’s unique approach emphasizes using cutting-edge molecular
profiling technologies to match patients with novel targeted therapies,
reflecting a personalized strategy to optimize cancer treatment. Dr.
Kurzrock has served as the Principal Investigator (PI) on more than 90
clinical trials, and overseen over 300 trials, mainly using novel targeted
molecules, several of which have gone on to FDA approval. She has published
over 500 peer-reviewed articles in a variety of elite medical journals.
In addition, she is Chair of the Southwest Oncology Group (SWOG) Early
Therapeutics Committee and on their Board of Governors and also serves
on the Board of Directors for NCCN and for WIN (World-Wide Innovative
Network for Personalized Cancer Therapy). She Chairs the Molecular
Diagnostic Clinical Trials committee for the American Association
of Cancer Institutes, as well as the Clinical Investigator Committee
for NCCN, and the Clinical Trials Committee for WIN. Dr Kurzrock has
been the PI of numerous grants and funding awards totaling over 50
million dollars. Dr. Kurzrock received her MD degree from the University
of Toronto.

Dr. Lahav is the Novartis Professor of Systems
Biology and Department Chair, Systems Biology at
Harvard Medical School. Dr. Lahav leads a department
at Harvard that uses the power of systems thinking,
across macro and micro scales, to unlock new insights
into health and disease. Dr. Lahav’s goal is to determine
why human cancer cells often show different responses to
the same treatment, and to identify new therapies that will
increase the efficacy of anti-cancer drugs. Dr. Lahav’s research
program works across traditional disciplinary boundaries.
Dr. Lahav’s lab has pioneered computational and quantitative
experimental approaches to studying the fate and behavior of
human cells in disease and health at the single-cell level. Dr.
Lahav’s work has yielded critical insights into the function and
behavior of tumor-suppressing mechanisms and their role in cellular
destiny. Dr. Lahav has been recognized through several awards and
honors including the Smith Family Award, Vilcek Prize for Creative
Promise, and Excellence in Teaching and Mentoring awards. Dr. Lahav
has established and organized leadership and management workshops
for postdocs and faculty, as well as developed programs for advancing
women in science. Dr. Lahav received her PhD in 2001 from the Technion,
Israel Institute of Technology. In 2003, she completed her postdoctoral
fellowship at the Weizmann Institute of Science in Israel. She then spent
a year at Harvard’s Bauer Center for Genomics Research, and in 2004 joined
the Department of Systems Biology at Harvard Medical School. In 2018 Lahav
became the Chair of the Department of Systems Biology.

Dr. Schiller is a well-published clinical investigator
in acute and chronic leukemias, multiple myeloma, and
other hematologic malignancies, as well as in stem cell
and bone marrow transplantation. He lectures extensively,
and has also written for the popular press. He is Immediate-Past
Chairman of the Los Angeles Museum of the Holocaust. His research
projects include clinical studies of new drugs, therapies, and bone
marrow/stem cell transplantation for patients with malignancies of the
blood or bone marrow such as leukemia, multiple myeloma, and lymphoma.
He has carried out studies of stem cell transplantation following high-dose
chemotherapy and radiation for acute myelogenous leukemia, one of the most
common types of leukemia in adults. He has ongoing studies using new drugs
and therapeutics for acute and chronic lymphocytic leukemia, acute and chronic
myelogenous leukemia, and multiple myeloma; he also has studies going on in
certain kinds of non-Hodgkin’s lymphoma and Sickle Cell Anemia. Dr. Schiller
received his MD from the USC School of Medicine.

Dr. George W. Sledge, Jr., M.D. is Professor and former Chief of Medical Oncology at Stanford University Medical Center.
Dr. Sledge served as a Ballve-Lantero Professor of Oncology of Medicine and Pathology
of Indiana University School of Medicine. He served as Co-Director of the breast cancer
program at the Indiana University Cancer Center, where he was a Professor of Medicine
and Pathology at the Indiana University Simon Cancer Center. Dr. Sledge specializes in
the study and treatment of breast cancer and directed the first large, nationwide study on the use of paclitaxel to treat advanced breast cancer.
His recent research focuses on novel biologic treatments for breast cancer.
He served as a Professor of Indiana University Cancer Center Breast Cancer
Program. He has also served as the chair of ASCO’s Education Committee, as a
member of the Department of Defense Breast Cancer Research Program’s Integration
Panel, as a member of the Food and Drug Administration’s Oncology Drug Advisory
Committee (ODAC), and as a member of the External Advisory Committee for The Cancer
Genome Atlas (TCGA) project. Dr. Sledge was awarded the Hope Funds for Cancer Research
2013 Award of ‘Excellence for Medicine’. He holds a B.A. from the University of Wisconsin
and an M.D. from Tulane University